Since both the activation of mTOR and NAD metabolism via NAMPT are involved in the therapeutic resistance of melanoma to BRAFi/MEKi, an outstanding question is whether in this context these two these two key molecular pathways are functionally interconnected. The gene discussed is NAMPT; the disease is melanoma.